Please login to the form below

MK-3475

This page shows the latest MK-3475 news and features for those working in and with pharma, biotech and healthcare.

be taken up by immune checkpoint inhibitors - BMS' nivolumab and Merck &Co's pembrolizumab (MK-3475) - which are currently in late-stage testing.

Merck could win anti-PD1 therapy race in Europe

Pembrolizumab (formerly lambrolizumab; MK-3475) is one of the highlights of Merck's R&D pipeline and is being evaluated across more than 30 types of cancer, with peak sales estimated
ASCO: Merck’s anti-PD1 impresses in skin and lung cancer

Promising MK-3475 immunotherapy to be known as pembrolizumab. New data on Merck &Co's recently-filed anti-PD1 drug pembrolizumab (MK-3475) suggest the drug could be a 'paradigm shift'
AZ starts pivotal trials of lung cancer immunotherapy

Meanwhile, Merck &Co's MK-3475 - filed for melanoma earlier this year - and Bristol-Myers Squibb's nivolumab for NSCLC are targeting a related receptor called PD1.
FDA grants priority review to Merck’s cancer antibody

The latest news from the FDA continues to back this belief and puts MK-3475 on course to be the first anti-PD-1 antibody approved in the US. . ... Merck has also signed agreements with rivals Pfizer, Amgen and Incyte to test MK-3475 in combination with
Novartis enters PD-1 race via CoStim acquisition

Of these Merck appears to be in the lead, as it has filed a rolling marketing submission for its MK-3475. ... therapies seems backed up by Merck's recent announcement of a series of collaborations on MK-3475 with other drugmakers.

More from news
Approximately 7 fully matching, plus 8 partially matching documents found.

Interview: Bruno Strigini, MSD

Here among the products he points to are the company's anti-PD-1 immunotherapy MK-3475, for which a rolling approval was filed earlier this year as a second-line
Pharma deals during February 2014

Merck &Co also signed three separate agreements with Amgen, Incyte and Pfizer to investigate combination regimes with its experimental anti-PD-1 immunotherapy, MK-3475 (see Box 1). MK-3475 was

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Bruno Strigini leaves Merck & Co for Novartis

Leading the field though is Strigini's former company Merck &Co, which has already filed MK-3475 in the US to treat advanced melanoma.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Add my company

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...

WHITE PAPER: Why do men die younger?: It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials: Here are some useful tips to help get your hands on authentically diverse stock photos....
Virtual congresses: video thrilled the cardio tsar: Chris Ross explores the key learnings from a year of virtual congresses...